The IASLC's History
In 1972, in response to the overwhelming need for collaboration and a growing concern for public health, Drs. David T. Carr, Oleg S. Selawry, Lawrence Broder, Clifton Mountain and George Higgins began building an international, multidisciplinary organization. In 1974, the group launched the International Association for the Study of Lung Cancer (IASLC) at their first formal meeting in Florence, Italy, having recruited more than 250 founding members from across the globe and with different perspectives.
Since then, the IASLC has grown into a professional, international organization of more than 8,000 members. Global experts have come to rely on the IASLC’s World Conference on Lung Cancer, Journal of Thoracic Oncology, as well as on its scientific programs and educational events to inform their practice of medicine, research and patient care. From doctors, nurses and allied health professionals to scientists, patients and advocates, the IASLC continues to unite people around the goal of eradicating lung and thoracic cancers.
order the 50TH ANNIVERSARY BOOK
You have all played a role in the success of the IASLC. Remember this occasion for years to come with the special 50th Anniversary edition of our history book! Don't miss out, order your copy of the book today.
History of the Chief Executive Officer
In 1994 the IASLC appointed Dr. Heine H. Hanson as its Executive Director, to manage the association's operations, initiatives and staff. Under the leadership of Dr. Hanson and his successors Dr. Paul Bunn Jr., Dr. Fred R. Hirsch, Dave Mesko, and Dr. Karen Kelly the IASLC experienced growth in terms of staffing, membership, activities, and overall impact.
History of The IASLC President
Throughout its long history, the IASLC has benefited from the strategic vision of its President. Many lung cancer luminaries have held this title since the mid-1970s when the organization was founded. Each leader has left an indelible mark, playing a fundamental role in its ongoing growth and development to ensure the IASLC remains a powerful resource in the fight against lung cancer.